(TPST) Tempest Therapeutics, Inc. SWOT Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(TPST) Tempest Therapeutics, Inc. Complete Analysis Pack
Make Confident Decisions Backed by Traceable Citations
This Tempest Therapeutics, Inc. SWOT Analysis gives a concise, company-specific review of strengths, weaknesses, opportunities, and threats to inform research, strategy, or investing; this page includes a genuine preview/sample of the report so you can judge style and substance before buying—purchase the full version to download the complete ready-to-use analysis.
Strengths
2 clinical-stage oncology assets
Tempest Therapeutics has two clinical-stage oncology assets, TPST-1495 and TPST-1120, so it is not tied to a single program. That lowers single-asset risk and gives the Company two shots in solid tumors, the largest oncology segment. A focused two-drug pipeline also makes development spending and trial execution easier to manage.
TPST-1495 dual EP2 and EP4 inhibition
TPST-1495 blocks both EP2 and EP4, two prostaglandin E2 receptors tied to tumor immune escape, so it may suppress the pathway more fully than a single-target drug. That dual hit is a clear strength in immuno-oncology, where pathway overlap often weakens selective approaches. It also gives Tempest Therapeutics, Inc. a more differentiated mechanism in a crowded field.
TPST-1120 PPAR alpha inhibition
TPST-1120 is a targeted peroxisome proliferator-activated receptor alpha blocker, giving Tempest Therapeutics, Inc. a second distinct small-molecule cancer mechanism alongside its other oncology programs. That broadens its scientific optionality across tumor biology and reduces reliance on one pathway. In a capital-light pipeline, one extra validated mechanism can matter a lot.
Built on small-molecule drug development
Tempest Therapeutics, Inc. is built on novel small-molecule drugs, which can support oral dosing and lower-cost manufacturing versus biologics. Small molecules also give Tempest clearer chemistry and a more scalable production path, which helps speed iteration across discovery and development.
This focus fits a lean oncology pipeline and can reduce the time and cost needed to test new candidates. In practice, the small-molecule model is easier to synthesize, ship, and scale than complex protein-based drugs.
- Oral dosing can improve patient convenience.
- Scalable chemistry helps manufacturing.
- Faster iteration supports pipeline progress.
Established company since 2011
Tempest Therapeutics, Inc. was founded in 2011, so by July 2026 it has more than 15 years of operating history. That long runway can help signal durability to investors, partners, and recruits. Based in South San Francisco, Tempest also sits in one of the U.S. biotech hubs, where proximity to talent, capital, and peers can speed hiring and industry ties.
- Founded in 2011
- 15+ years of operating history by July 2026
- South San Francisco biotech access
Two Clinical Assets, One Focused Oncology Pipeline
Tempest Therapeutics, Inc. has two clinical-stage oncology assets, TPST-1495 and TPST-1120, which lowers single-program risk and keeps focus on solid tumors. TPST-1495’s dual EP2/EP4 blockade and TPST-1120’s distinct PPARα mechanism give the Company two differentiated small-molecule shots in oncology. Founded in 2011 and based in South San Francisco, it also benefits from long operating history and biotech access.
| Strength | Data |
|---|---|
| Pipeline | 2 clinical assets |
| Founding | 2011 |
| HQ | South San Francisco |
What is included in the product
Detailed Word Document
Provides a clear SWOT framework for analyzing Tempest Therapeutics, Inc.’s business strategy
Editable Excel File
Provides a quick SWOT snapshot for Tempest Therapeutics, Inc. to simplify strategic review and decision-making.
Reference Sources
Lists primary reputable sources validating Tempest Therapeutics’ market, pricing, and competitive assumptions for fast, traceable due diligence.
Weaknesses
No approved products
Tempest Therapeutics, Inc. has 0 approved products and no marketed oncology therapy, so it still generates 0 product sales. The business remains in clinical development, which leaves it fully dependent on future trial success and regulator approval. Until a program clears Phase 3 and wins approval, revenue stays absent and cash burn stays tied to R&D.
Phase 1 stage pipeline
Tempest Therapeutics, Inc. still has a Phase 1-only pipeline: TPST-1495 and TPST-1120 are both in early solid-tumor studies, which means high clinical failure risk and limited proof of efficacy. With no late-stage asset or approved product, the company must clear Phase 2, Phase 3, and FDA review before any registration path. That long runway also keeps funding and dilution risk high.
Limited pipeline concentration
Tempest Therapeutics, Inc. is still highly dependent on two lead programs, TPST-1495 and TPST-1120. That narrow pipeline means a setback in either asset can hit the story hard, with little near-term internal backup. In biotech, concentration like this raises trial-risk because one negative readout can erase most of the company’s value driver.
Biology risk in novel mechanisms
Tempest Therapeutics, Inc. faces high biology risk because both programs lean on novel cancer pathways, including prostaglandin signaling and PPAR alpha. These targets are less proven in patients than standard oncology targets, so human data can break early on efficacy or safety. With only a small clinical set for any first-in-class readout, one weak signal can quickly reset the thesis.
- Novel targets are harder to validate in humans.
- Weak efficacy or safety can end programs fast.
- First-in-class biology raises clinical failure risk.
High funding dependence
Tempest Therapeutics, Inc. has no product revenue, so oncology trials, manufacturing scale-up, and FDA work must be funded through outside capital. In its latest filings, the Company showed recurring operating losses and ongoing cash burn, which makes dilution or debt raises more likely. That dependence can slow trial pace, force program cuts, or delay regulatory steps if markets tighten.
- No commercial cash flow.
- Trials need heavy upfront spend.
- External capital can dilute holders.
- Funding gaps can delay milestones.
Tempest’s Early-Stage Pipeline Leaves It Dependent on Outside Capital
Tempest Therapeutics, Inc. has 0 approved products and 0 product sales, so it still depends on outside capital to fund R&D. Its pipeline is only Phase 1, with TPST-1495 and TPST-1120 as the two main assets, which keeps clinical failure risk high.
| Weakness | Key data |
|---|---|
| Commercial gap | 0 approved products; 0 sales |
| Pipeline risk | 2 lead assets; Phase 1 only |
| Funding risk | No product cash flow |
Get Your Copy
Tempest Therapeutics, Inc. Reference Sources
This is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, showing Tempest Therapeutics’ key strengths, weaknesses, opportunities, and threats; buy to unlock the complete, editable version with detailed insights and data.
Opportunities
Solid tumor market opportunity
Tempest Therapeutics, Inc.’s lead assets target solid tumors, which make up most adult cancers. The American Cancer Society projected about 2.04 million new U.S. cancer cases in 2025, and solid tumors account for the bulk of that demand. If Tempest shows strong clinical data, it could draw broad partner interest and larger commercial upside.
Immune microenvironment targeting
Tempest Therapeutics is exploring TREX-1, an enzyme that helps control the innate immune response in cancer, and that opens a path into tumor immune biology. If the program works, it could add a second immuno-oncology lever alongside its current cancer pipeline. One successful target can matter a lot in a small biotech.
First-in-class or differentiated profile potential
Tempest Therapeutics, Inc. has 2 lead assets, TPST-1495 and TPST-1120, that hit distinct, nonstandard oncology pathways, which can help it stand out in a crowded field. If either shows early efficacy, the first-in-class angle can improve partnering interest and support deal talks. That novel biology also leaves room for niche settings and combination regimens where 1 clear biomarker or responder group can matter.
Combination therapy potential
Tempest Therapeutics, Inc. can pair its cancer mechanisms with approved or experimental agents, which fits how solid-tumor trials are often run in multi-drug regimens. That widens trial design choices and can improve the chance of finding active combinations in harder-to-treat tumors. It also boosts market relevance if the data support use with standard-of-care therapies.
- Fits common solid-tumor combo trial design
- May widen partner and indication options
- Could lift commercial relevance with SOC use
Partnership and licensing upside
Tempest Therapeutics, Inc. can use early-stage assets like amezalpat to draw larger biotech or pharma partners, since deal flow often starts before late-stage data. A licensing or co-development pact can bring non-dilutive cash and outside trial know-how, which matters for a small company with limited capital. A pipeline that spans more than one mechanism also gives Tempest Therapeutics, Inc. more leverage in negotiations and more than one path to value.
- Early assets can spark partner interest
- Deals can fund trials without dilution
- Multiple mechanisms improve deal optionality
Tempest’s Big Shot in a Huge Solid-Tumor Market
Tempest Therapeutics, Inc. can benefit from a large solid-tumor market: the American Cancer Society projected about 2.04 million new U.S. cancer cases in 2025, and solid tumors drive most demand. If TPST-1495 or TPST-1120 shows cleaner efficacy, Tempest Therapeutics, Inc. could gain partner interest and more trial options.
| Opportunity | Data |
|---|---|
| Solid tumors | 2.04M U.S. cases, 2025 |
| Partnerships | Non-dilutive funding |
Threats
Clinical trial failure risk
Phase 1 oncology programs have one of the lowest success rates, with only about 10% of candidates reaching approval. TPST-1495 and TPST-1120 still need clear safety and early activity data to justify larger, costlier studies. If human data disappoints, Tempest Therapeutics, Inc. could see a sharp hit to pipeline value and investor confidence.
Competition in oncology
Solid tumor oncology is crowded, with Big Pharma setting a very high bar: Merck’s Keytruda posted $29.5 billion in 2024 sales, showing how hard it is for smaller players to win share. Better-funded rivals can move faster on trials, combos, and regulatory reach, which can squeeze Tempest Therapeutics, Inc.’s differentiation. That pressure can also weaken partnering leverage and pricing power.
Regulatory uncertainty
Regulatory uncertainty is a real threat because Tempest Therapeutics, Inc.'s programs must clear FDA trial design, safety, and endpoint checks before they can move forward. A single protocol change or safety signal can trigger a hold, add months, and force more spending; late-stage oncology trials can cost tens of millions of dollars. Any setback can stretch timelines and pressure cash runway.
Capital market volatility
Capital market volatility is a real threat for Tempest Therapeutics, Inc. because biotech funding can tighten fast, and development-stage companies with no approved products have little cushion. If risk appetite falls, Tempest may need to raise cash at weaker prices, which can increase equity dilution and pressure existing shareholders.
- No approved products yet
- Funding access can shift fast
- Weak markets can dilute shares
For a company still depending on external capital, even a short funding gap can slow trials, delay milestones, or force less favorable financing terms.
Safety and tolerability risk
Safety and tolerability remain a real threat for Tempest Therapeutics, Inc. because novel oncology mechanisms can trigger human toxicities that did not show up in preclinical work. One safety signal in early dose-escalation can cap dose, block expansion, or narrow combo use, and that risk applies to both amezalpat (TPST-1120) and the TREX-1 program.
Tempest Therapeutics, Inc. is still a very small biotech, so one adverse-event readout can move the whole story. If the current clinical asset needs dose cuts or excludes combinations, the upside case weakens fast, and the 1 active oncology platform plus early-stage TREX-1 work face the same safety bar.
- Novel targets can create unexpected human toxicity.
- Early safety signals can limit dose and expansion.
- Combo use may be cut if tolerability weakens.
- TREX-1 work carries the same risk.
Tempest Faces Brutal Trial Odds as Keytruda Raises the Bar
Tempest Therapeutics, Inc. faces high trial risk: Phase 1 oncology programs have only about a 10% approval rate. Its lead assets still need clean safety and early efficacy data, and any safety signal can halt dose, cut combinations, or weaken value. Big Pharma rivals like Merck, with Keytruda at $29.5 billion in 2024 sales, raise the bar and squeeze pricing power.
| Threat | Data |
|---|---|
| Trial success | ~10% approval |
| Key rival | Keytruda $29.5B |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.